Phyllodulcin as a sugar complement exerts anti‐diabetic effects in db/db mouse

Abstract

Type 2 diabetes mellitus is a chronic metabolic disease and characterized by insulin resistance, and is frequently accompanied by obesity or overweight. Phyllodulcin, a dihydroisocoumarin, is a well‐known sweetener in Hydrangea macrophylla var. The aim of study was to evaluate the anti‐diabetic potential of phyllodulcin in C57BL/KsJ‐db/db mice. In the present study, male mice were randomized into five groups; (1) a control group of C57BL/6 mice that received AIN93G (Ctrl), (2) a diabetic control group of C57BL/KsJ‐db/db mice that received AIN93G (DB), (3) a 20 mg/kg body weight (b.w.) of stevioside supplemented DB mice (SVS 20), (4) a 10 mg/kg b.w. of phyllodulcin supplemented DB mice (P 10), and (5) a 20 mg/kg b.w. of phyllodulcin (P 20) supplemented DB mice (P 20). The water and food intake was significantly lower in the SVS 20, P10 and P20 group compared to that of DB group. Phyllodulcin supplementation suppressed the levels of fasting blood glucose and HbA1c. In addition, the plasma TG levels in the SVS 20, P 10 and P 20 groups were significantly lower than that of DB group. Furthermore, the expression phosphoenolpyruvate carboxylase (PEPCK) was significantly lower in stevioside and phyllodulcin supplementation group and the expression of glucose transporter 4 (GUT4) was significantly higher in phyllodulcin supplemented group. In conclusion, phyllodulcin may be useful for improving blood glucose intolerance and abnormalities of diabetic conditions.Support or Funding InformationThis research was supported by High Value‐added Food Technology Development Program (Project number: 313024‐03‐2‐HD040), Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea), and Brain Korea 21 Plus (Project No. 22A20130012143).